Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer (AIVAA)
Lung Cancer

About this trial
This is an interventional supportive care trial for Lung Cancer
Eligibility Criteria
Inclusion Criteria: Adults (≥18 years of age) seen at TOHCC with stage IIIB or IV primary non-small cell lung cancer Eligible and scheduled for first line platinum-doublet chemotherapy with or without concurrent immunotherapy Exclusion Criteria: ECOG status greater than 2 Previously received IVC within 6 months prior to randomization Biochemical deficiency in G6PD Estimated Glomerular Filtration Rate (eGFR) less than 45 mL/min Currently taking insulin or warfarin History of severe renal dysfunction or hemochromatosis Previously undergone cytotoxic chemotherapy or immunotherapy within 12 months prior to randomization If pregnant or planning to become pregnant: not a carrier of the gene for G6PD deficiency Currently taking an investigational product or participation in an investigational study within the past 30 days Any reason which, under the discretion of the Principal Investigator or delegate, would preclude the patient from participating
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Intravenous Vitamin C
Normal Saline
1g/kg IVC administered twice weekly for 6 months.
Equivalent volume normal saline administered twice weekly for 6 months.